Per Persson, CEO of Acarix has been selected as Innovation Leader, to present at the LSI 2021 summit, CA, US next spring 

At LSI 2021, Mr. Persson will share the story of Acarix and provide timely updates to an audience of medtech investors, strategics, and industry insiders.

Objective: Provide a much needed in-person investment/networking event focused on medtech innovation

When: February 17-19, 2021

Where: The Ritz-Carlton, Dana Point, CA


Life science medtech-summit, CA, US 2021

About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix.

For more information, please visit www.acarix.com.